Xeris Biopharma Holdings, Inc.
No enriched coverage for $XERS in the last 7 days.
Xeris Biopharma officer Beth Hecht plans to sell 16,666 shares, valued at $159,326.96, on October 1, 2026. She previously sold 16,666 shares each in August and September 2026 under a 10b5-1 plan, according to filings.
Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.
Lundbeck (LON:0ND5) has shown interest in acquiring Xeris Pharmaceuticals (NASDAQ:XERS), according to Bloomberg. Xeris, focused on endocrine and rare disease therapies, stated it is not for sale. Lundbeck, specializing in neurological and psychiatric conditions, may expand into rare endocrine disorders through this potential deal. Discussions are preliminary, and no formal offer has been made.
Recent XERS coverage spans financial news, mergers & acquisitions and earnings.
In the last 30 days, XERS insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($595K). The most active reporter was McCulloch Kevin, See Remarks, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may create modest selling pressure on XERS.
Phase‑3 initiation may drive further buying.
Potential acquisition could drive XERS stock higher as investors price in a takeover premium.
The acquisition rumor drives short-term buying pressure on XERS.
Improved dosing precision may de‑risk the XP-8121 program and support future regulatory filings.
AlphAI scores every news story that mentions XERS with an AI model for sentiment and relevance, and aggregates insider trades from Xeris Biopharma Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Xeris Biopharma officer Beth Hecht plans to sell 16,666 shares, valued at $159,326.96, on October 1, 2026. She previously sold 16,666 shares each in August and September 2026 under a 10b5-1 plan, according to filings.
1 min readSeveral biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.
2 min readLundbeck (LON:0ND5) has shown interest in acquiring Xeris Pharmaceuticals (NASDAQ:XERS), according to Bloomberg. Xeris, focused on endocrine and rare disease therapies, stated it is not for sale. Lundbeck, specializing in neurological and psychiatric conditions, may expand into rare endocrine disorders through this potential deal. Discussions are preliminary, and no formal offer has been made.
2 min readXeris Biopharma (XERS) shares rose 6% after reports that H Lundbeck (HLBBF) is considering an acquisition, despite Xeris stating it is not for sale. Xeris's P/S ratio is 5.2x, above its historical median and industry average, reflecting growth expectations. The company's GF Score is 68, indicating moderate quality with strong growth but weak profitability. Insider activity shows no buying and $4.8M in selling, while institutional interest is mixed.
2 min readmedmix' Drug Delivery (Haselmeier) partners with Xeris Pharmaceuticals to develop XP-8121, a once-weekly hypothyroidism treatment. The D-Flex™ pen injector, with high dose accuracy, will be used for precise delivery of the drug. Both companies emphasize the importance of accurate dosing for narrow therapeutic index drugs. medmix' shares are traded on the SIX Swiss Exchange (SIX: MEDX).
2 min readXeris (XERS) Q2 2026 earnings call said it retired its convertible notes, eliminating nearly $3 million in annual interest expense. The company raised full-year 2026 total revenue guidance to $385 million to $390 million. Q2 net product revenue was $91 million (+34% YoY) and total revenue $92.1 million (+29%). Recorlev net revenue was $56.8 million (+81% YoY), Gvoke about $23 million, and Keveyis nearly $12 million. It also reported new U.S. patent allowances for Keveyis and XP-8121.
7 min readXeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81% year-over-year to approximately $57 million Tightens full
6 min readXeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. xers-20260715 ☐ 0001867096 0001867096 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Jul
3 min readMcCulloch Kevin (See Remarks) sold 90,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $8.03 ($0.72M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
1 min readXeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. xers-20260629 ☐ 0001867096 0001867096 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Jun
2 min read
